On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with  Creative Acquisition Corp. ("CAC"), pursuant to which the Company purchased 4,000,000 shares of common stock of BioDefense, Inc. ("BioDefense") from CAC for an aggregate purchase price consisting of $200,000 in cash and 1,000,000 shares of the Company’s common stock.  After giving effect to the transactions under the Purchase Agreement, the Company owns 16,000,000 shares of BioDefense common stock, constituting 80% of the outstanding shares of common stock of BioDefense, and CAC owns 4,000,000 shares of BioDefense common stock, constituting 20% of the outstanding shares of common stock of BioDefense.  Timothy Warbington, the President and Chief Executive officer of the Company, is also the Chairman and Chief Executive Officer of CAC and indirectly owns all of its outstanding shares of capital stock.